BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22562298)

  • 1. Effect of the Honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection.
    Hong SW; Jee D
    Eur J Ophthalmol; 2012; 22(4):615-9. PubMed ID: 22562298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique.
    Kim KS; Jee D
    Jpn J Ophthalmol; 2011 Nov; 55(6):632-7. PubMed ID: 21947489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
    Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
    Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort.
    Knecht PB; Michels S; Sturm V; Bosch MM; Menke MN
    Retina; 2009 Sep; 29(8):1175-81. PubMed ID: 19734766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angled transscleral intravitreal injection: a crossover study.
    Mehta MC; Finger PT
    Eur J Ophthalmol; 2015; 25(2):173-6. PubMed ID: 25384968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
    Kim JE; Mantravadi AV; Hur EY; Covert DJ
    Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).
    Sharei V; Höhn F; Köhler T; Hattenbach LO; Mirshahi A
    Eur J Ophthalmol; 2010; 20(1):174-9. PubMed ID: 19927267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
    Lee K; Yang H; Lim H; Lew HM
    Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major factors affecting intraocular pressure spike after intravitreal ranibizumab injection: Vitreous reflux and its amount.
    Uyar E; Ulas F; Sahin S; Celebi S
    Eur J Ophthalmol; 2019 Jul; 29(4):361-367. PubMed ID: 30947538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.
    Benz MS; Albini TA; Holz ER; Lakhanpal RR; Westfall AC; Iyer MN; Carvounis PE
    Ophthalmology; 2006 Jul; 113(7):1174-8. PubMed ID: 16647122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
    Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
    Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
    Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
    Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
    Falkenstein IA; Cheng L; Freeman WR
    Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.
    Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
    Acta Ophthalmol; 2014 Nov; 92(7):e530-9. PubMed ID: 24373344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
    Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
    Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab.
    Lee JW; Park H; Choi JH; Lee HJ; Moon SW; Kang JH; Kim YG
    BMC Ophthalmol; 2016 May; 16():69. PubMed ID: 27245159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
    Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
    Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.